Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL who have received chimeric antigen receptor T-cell therapy against CD19 (CART-19) are now available.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Long-term study with dementia patients
Ginkgo biloba extract significantly reduces the risk of progression
- Intestinal microbiome
Complex and fragile system of microorganisms
- Cancer prevention
Poorer prognosis for men who avoid prostate cancer screening
- Liver steatosis with metabolic dysfunction
New nomenclature for non-alcoholic fatty liver disease
- Diabetes mellitus
Treatment of comorbidities in older people
- Type 2 diabetes: PAD and diabetic foot syndrome
Prevention is better than cure – don’t miss the risk foot
- Prostate cancer
High-resolution ultrasound could diagnose prostate cancer faster
- Chronic lung diseases